Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut (CDX-110)
Expanded access is no longer available for this treatment.
First Posted: March 3, 2017
Last Update Posted: October 18, 2017
Information provided by (Responsible Party):
Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to rindopepimut in patients with EGFRvlll expressing recurrent glioblastoma will be considered.
What is Expanded Access?
Available for Intermediate-size Population
|Official Title:||Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut (CDX-110)|
Further study details as provided by Celldex Therapeutics:
Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination.
Contacts and Locations
No Contacts or Locations Provided